TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 46 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Review, H1 2016', provides in depth analysis on TAR DNA-Binding Protein 43 (TDP-43) targeted pipeline therapeutics. 

The report provides comprehensive information on the TAR DNA-Binding Protein 43 (TDP-43), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for TAR DNA-Binding Protein 43 (TDP-43)
- The report reviews TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics and enlists all their major and minor projects 
- The report assesses TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for TAR DNA-Binding Protein 43 (TDP-43)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding TAR DNA-Binding Protein 43 (TDP-43) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
TAR DNA-Binding Protein 43 (TDP-43) Overview 6
Therapeutics Development 7
TAR DNA-Binding Protein 43 (TDP-43) - Products under Development by Stage of Development 7
TAR DNA-Binding Protein 43 (TDP-43) - Products under Development by Therapy Area 8
TAR DNA-Binding Protein 43 (TDP-43) - Products under Development by Indication 9
TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
TAR DNA-Binding Protein 43 (TDP-43) - Products under Development by Companies 12
TAR DNA-Binding Protein 43 (TDP-43) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 17
TAR DNA-Binding Protein 43 (TDP-43) - Companies Involved in Therapeutics Development 19
Biogen, Inc. 19
ImStar Therapeutics Inc. 20
Primary Peptides, Inc. 21
SK Biopharmaceuticals Co., Ltd. 22
TauRx Therapeutics Ltd. 23
TAR DNA-Binding Protein 43 (TDP-43) - Drug Profiles 24
IMS-088 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
NI-205 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Small Molecule to Inhibit TDP-43 for Amyotrophic Lateral Sclerosis - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
Small Molecules to Inhibit TANA for ALS, Dementia and Alzheimer's Disease - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Small Molecules to Inhibit TDP-43 for Amyotrophic Lateral Sclerosis - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Synthetic Peptide to Inhibit TDP-43 for Amyotrophic Lateral Sclerosis - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
TRx-0237 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
TAR DNA-Binding Protein 43 (TDP-43) - Dormant Projects 33
TAR DNA-Binding Protein 43 (TDP-43) - Featured News & Press Releases 34
Nov 23, 2015: Aquinnah Pharmaceuticals Receives $680,000 Grant from NINDS To Advance New Therapies for ALS 34
Jan 20, 2015: First Evidence of Potential Efficacy of Tau Aggregation Inhibitor Therapy in Alzheimer's Disease 34
Sep 25, 2014: Proteome Sciences signs $2m contract with Genting TauRx Diagnostic Centre to develop diagnostic panels to detect Alzheimer's disease and monitor treatment efficacy 35
Sep 22, 2014: TauRx Therapeutics Achieves Enrolment Target for Second Phase III Clinical Trial of LMTX in Alzheimer's Disease 36
Jul 15, 2014: TauRx Therapeutics Achieves Enrolment Target in the First of Its Two Phase III Clinical Trials of LMTX in Alzheimer's Disease 37
Jun 18, 2014: University Hospitals Case Medical Center now enrolling patients in clinical trial for Frontotemporal Dementia 38
Mar 27, 2014: TauRx Chairman to present at scientific symposium focused on advances in Alzheimer's treatments 39
Mar 24, 2014: TauRx Therapeutics to present at Social Care Conference in London on 25th 40
Jan 09, 2014: First German Patients Enroll in Phase 3 Clinical Trials of LMTX for Alzheimer's Disease 40
Jan 06, 2014: TauRx Expands Alzheimer's Clinical Trials in the United States 41
Nov 26, 2013: ImStar Therapeutics Selects Lead Drug Candidate for ALS 41
Oct 03, 2013: Professor Claude Wischik, Chairman of TauRx, highlights future consequences of Alzheimer's Disease at annual psychogeriatric conference in Korea 42
Sep 19, 2013: TauRx achieves milestone in global Phase 3 clinical trials of LMTX for Alzheimer's Disease 42
Jun 10, 2013: TauRx Therapeutics And Toronto Memory Program Announce Canadian Launch Of Phase III Clinical Trials Of LMTX For Treatment Of Alzheimer's Disease 43
May 22, 2013: TauRx Therapeutics Enrolls First Patient In Phase III Clinical Trials Of LMTX For Treatment Of Alzheimer's Disease In UK 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 45
Disclaimer 46

List of Tables

Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Products under Development by Companies, H1 2016 13
Assessment by Monotherapy/Combination Products, H1 2016 14
Number of Products by Stage and Mechanism of Action, H1 2016 15
Number of Products by Stage and Route of Administration, H1 2016 16
Number of Products by Stage and Molecule Type, H1 2016 18
Pipeline by Biogen, Inc., H1 2016 19
Pipeline by ImStar Therapeutics Inc., H1 2016 20
Pipeline by Primary Peptides, Inc., H1 2016 21
Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 22
Pipeline by TauRx Therapeutics Ltd., H1 2016 23
Dormant Projects, H1 2016 33